Last updated on June 2019

QUILT-2.023: A Study of ALT-803 a Fusion Protein Activator of Natural Killer and T-Cells in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC.

Brief description of study

This is a phase 2, open-label, randomized study to compare the safety and efficacy of combination therapy with ALT-803 and pembrolizumab (experimental arm) versus pembrolizumab alone (control arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.

Clinical Study Identifier: NCT03520686

Find a site near you

Start Over

Mercy Research Joplin

Joplin, MO United States
  Connect »